Efficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label Extension - PubMed

4 hours ago

Pegcetacoplan demonstrated significant reduction in subfoveal geographic atrophy (GA) growth over 36 months in age-related macular degeneration patients.
In subfoveal GA eyes, monthly pegcetacoplan reduced GA growth rate by 21% and every-other-month dosing by 19% over 36 months.
Efficacy increased between months 24 and 36, with 31% and 25% reductions in GA growth rate for monthly and every-other-month treatments, respectively, compared to projected sham.
Microperimetry showed significant reduction in absolute scotoma formation with monthly pegcetacoplan at both 24 and 36 months compared to sham crossover.
Safety profile remained consistent with previous trials, and most subfoveal GA patients retained some vision (84% had BCVA ≥20/200 at baseline).
The study highlights the importance of treating subfoveal GA to preserve remaining central vision and slow further vision loss.

Hasty Briefsbeta